Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IL-2 after High-Dose Ara-C for AML in First Remission
NCT00136448Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Feb 1993
- Primary completion
- Sep 2007
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of aldesleukin in acute myeloid leukemia (AML), sponsored by Dana-Farber Cancer Institute. Started Feb 1993; status: completed.
02
Drugs
aldesleukin
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00136448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00136448.